NASCOLA is a nonprofit organization whose mission is to improve diagnostic coagulation testing, through proficiency testing, critical evaluation, guideline development, enhanced communication, collaboration, education
Clinical Laboratories can join NASCOLA as an “Institutional Member”. Companies (that manufacture, distribute, or provide other services in the field of coagulation) can join NASCOLA as “Associate Members.” Individual memberships in NASCOLA are also available. Institutional and Associate Members have the option to participate in the proficiency testing/external quality assessment (PT/EQA) program. Additional privileges, for all categories of NASCOLA membership, include NASCOLA website access to educational and resource materials (open for all interested specialized coagulation laboratory staff of an Institutional Member, and to all interested company representatives of Associate Members). Trainees (physician and MT) of NASCOLA institutional members are also eligible to join (membership complimentary).
NASCOLA holds 1 major scientific conference per year, and 1 general membership meetings, often in conjunction with NASCOLA scientific conferences and other national meetings (THSNA, ISLH).
NASCOLA is pleased to offer Proficiency Testing Modules for nonregulated, specialized coagulation analytes at substantially lower costs than competitors.PT/EQA challenges are scheduled for March, May, August and November 2024. For optimal assessments of testing quality, PT/EQA challenges include normal and abnormal clinical samples (distributed as lyophilized sample sets). Participants receive individualized, confidential reports. Summary analyses for all modules are posted on the NASCOLA website. NASCOLA annual fees (by membership category) and 2024 Module Programs (available to Institutional and Associate Members only) are outlined in detail in the table.
NOTE: Orders placed later than December 9,
If you would like to join
Please see the table for additional information regarding the NASCOLA Proficiency Testing Program.
2024 NASCOLA Fees and Module Programs
MAIN PROGRAM | ||||||
---|---|---|---|---|---|---|
Description | Number of surveys | Survey(s) 2024 | ||||
M1 | M2 | M3 | M4 | |||
Dispatch date | Mar | May | Aug | Nov | ||
Thrombophilia – I Antithrombin (activity and antigen), Protein C (activity [chromogenic and clotting] and antigen), Protein S activity, Protein S antigen (total and free) | 4 | √ | √ | √ | √ | |
Thrombophilia – II APC Resistance | 4 | √ | √ | √ | √ | |
Lupus Anticoagulant / Antiphospholipid Antibodies | 4 | √ | √ | √ | √ | |
Coagulation Factor – I Factor VIII (clot and chromogenic), IX:C, XI:C and XII:C | 4 | √ | √ | √ | √ | |
Coagulation Factor – II Factor II:C, V:C, VII:C and X:C | 4 | √ | √ | √ | √ | |
Von Willebrand Factor parameters (antigen, activity, collagen binding, multimers, Factor VIII) | 4 | √ | √ | √ | √ | |
ADAMTS13 – I (activity and antigen) | 4 | √ | √ | √ | √ | |
ADAMTS13 – II (antibodies) | 2 | √ | √ | |||
Factor XIII (activity and antigen) | 4 | √ | √ | √ | √ | |
Fibrinolysis – I Plasminogen, Antiplasmin | 4 | √ | √ | √ | √ | |
Fibrinolysis – II t-PA, PAI-1 | 4 | √ | √ | √ | √ | |
Factor VIII inhibitor (includes immunologic inhibitor study) | 2 | √ | √ | |||
Factor IX Inhibitor | 2 | √ | √ | |||
Thrombin Generation Test | 2 | √ | √ | |||
HIT – I (immunological testing) | 2 | √ | √ | |||
Unfractionated Heparin Monitoring (anti-Xa) | 4 | √ | √ | √ | √ | |
Low-Molecular Weight Heparin Monitoring (anti-Xa) | 4 | √ | √ | √ | √ | |
Orgaran (anti-Xa) | 2 | √ | √ | |||
Fondaparinux (anti-Xa) | 2 | √ | √ | |||
Rivaroxaban (anti-Xa) | 2 | √ | √ | |||
Apixaban (anti-Xa) | 2 | √ | √ | |||
Edoxaban (anti-Xa) | 2 | √ | √ | |||
Argatroban (anti-IIa, dTT) | 2 | √ | √ | |||
Dabigatran (anti-IIa, dTT) | 2 | √ | √ | |||
Homocysteine | 4 | √ | √ | √ | √ |
ROTEM/TEG PROGRAM | ||||
---|---|---|---|---|
Description | Number of surveys | Survey(s) 2024 | ||
T1 / T2 | T3 /T4 | |||
Dispatch date | Mar/ May | Aug/Nov | ||
ROTEM delta □ 1 instrument / 1 set of samples ROTEM □ 2 instruments / 2 sets of samples ROTEM □ 3 instruments / 3 sets of samples ROTEM | 4 | √ / √ | √ √ |
|
ROTEM sigma □ 1 instrument / 1 set of samples ROTEM □ 2 instruments / 2 sets of samples ROTEM □ 3 instruments / 3 sets of samples ROTEM | 4 | √ √ | √ √ |
|
TEG □ 1 instrument / 1 set of samples TEG □ 2 instruments / 2 sets of samples TEG □ 3 instruments / 3 sets of samples TEG | 4 | √ √ | √ √ |
|
D-DIMER PROGRAM | ||||||
---|---|---|---|---|---|---|
Description | Number of surveys | Survey(s) 2023 | ||||
D1 | D2 | D3 | D4 | |||
Dispatch date: all samples sent together in February 2022 | ||||||
D-Dimer 1 set of | 4 | √ | √ | √ | √ |
SCREEN PROGRAM | ||||||||
---|---|---|---|---|---|---|---|---|
Description | Number of surveys | Survey(s) 2023 | ||||||
Dispatch date: all samples sent together in March 2023 | S1 | S2 | S3 | S4 | S5 | S6 | ||
Screen-I: APTT, PT/INR 1 set of | 8 | √ | √ | √ | √ | √ | √ | |
Screen-II: Thrombin Time and Reptilase time 1 set of | 8 | √ | √ | √ | √ | √ | √ |
DESCRIPTION | NUMBER OF SURVEYS | SURVEY CODES | |||||
HAEMOPHILIA PROGRAM | |||||||
Haemophilia Factor VIII (clot and chromogenic activity) Factor IX (clot and chromogenic activity) | 4 | 2024-H1 | 2024-H2 | 2024-H3 | 2024-H4 | | |
Factor VIII inhibitor | 2 | 2024-H2 | 2024-H4 | ||||
Factor IX Inhibitor | 2 | 2024-H1 | 2024-H3 | ||||
Emicizumab | 2 | 2024-H2 | 2024-H4 | ||||
Kovaltry (Bayer) | 2 | 2024-H1 | 2024-H3 | ||||
Jivi (Bayer) | 2 | 2024-H1 | 2024-H3 | ||||
Esperoct (Novo Nordisk) | 2 | 2024-H2 | 2024-H4 | ||||
NovoEight (Novo Nordisk) | 2 | 2024-H2 | 2024-H4 | ||||
Refixia (Novo Nordisk) | 2 | 2024-H2 | 2024-H4 |
DESCRIPTION | NUMBER OF SURVEYS | SURVEY CODES | |||||
Fibrin(ogen) Degradation Products | |||||||
FDP | 4 | 2024-F1 | 2024-F2 | 2024-F3 | 2024-F4 |
DESCRIPTION | NUMBER OF SURVEYS | SURVEY CODES | |||||
APTT / PT MIXING TEST PROGRAM | |||||||
APTT / PT Mixing Test | 4 | 2024- Mix1 | 2024- Mix2 | 2024- Mix3 | 2024- Mix4 |
POCT INR QC PROGRAM No annual subscription fee applicable if only participating in the POCT INR QC Program. | ||||||
Description | Surveys | |||||
2024-Q1 | 2024-Q2 | 2024-Q3 | 2024-Q4 | |||
Dispatch dates | Feb | Apr | July | Oct | ||
POCT INR QC Program for CoaguChek INR monitors (any type) | √ | √ | √ | √ |
OTHER SURVEYS | ||||
---|---|---|---|---|
Description | Organized by | Number of surveys | Survey period(s) 2023 | |
Post Analytical Platelet Function EQA (electronic survey) | Nascola, USA | 2 | Spring, Autumn | |
Platelet Dense Granule exercise (electronic survey) | Nascola, USA | 2 | Spring, Autumn | |
Case studies on bleeding disorders (distribution separately from the regular surveys) | ECAT/ INSTAND | 1 | Autumn | |
Pre- and post-analytical electronic surveys in haemostasis | ECAT | 1 | Autumn |
MOLECULAR BIOLOGY (in cooperation with the DGKL, Germany) | |||||
---|---|---|---|---|---|
MOLECULAR GENETICS MG1 | |||||
Survey name | Description | Num- ber of sur- veys | Surveys 2024 | ||
MG1 1/24 | MG1 2/24 | ||||
Dispatch date | March | Sept | |||
MG1 Set A | FV-Leiden, Prothrombin, MTHFR(C677T, A1298C), PAI-I 4G5G | 2 | √ | √ | |
MG1 Set B | FXIII V34L, GPIIIa, βFib (g455a), VKORC1 (G-1639A/C1173T), FXII c46t, FV-H1299R | 2 | √ | √ | |
MG1 Set C | a1 PI, Apo E, ApoB100, ACE, CETP | 2 | √ | √ | |
MG1 Set D | Aldo B (149,147,334), HFE (H63D, C282Y, S65C), LCT c-13910t, NOD2 (R702W, G908R, L1007fins C) | 2 | √ | √ | |
MG1 Set E | M. Wilson (ATP7B-C3207A), FSAP (Marburg-I), ITGA2 Gplalla C807T, Col1A1 SP1, VDR (Bsml/Apal,Taql) | 2 | √ | √ | |
MG1 Set F | Factor VII (R353Q), AT3 Cambridge Typ I/II, CYP3A5*3 | 2 | √ | √ | |
MOLECULAR GENETICS MG2 | |||||
Survey name | Description | Num- ber of sur- veys | Surveys 2024 | ||
MG2 1/24 | MG2 2/24 | ||||
Dispatch date | March | Sept | |||
MG2 Set A | TMPT, CYP2C8 (K399R), CYP2C9 *2/*3, UGT1A1 (*28), DPYD *2A (Ex 14 skipping), BCHE A/K, DPYD *13, DPYD D949V (rs67376798) | 2 | √ | √ | |
MG2 Set B | K-Ras: Codon 12/13/61, BRAF V600E, BRAF V600K, cKit D816V | 2 | √ | √ | |
MG2 Set C | HLA-B27, TNF alpha (238, 308) | 2 | √ | √ | |
MG2 Set D | CYP2D6, CYP2C19 (*2/*17), CYP2C19*3 | 2 | √ | √ | |
MG2 Set E | HLA B*5701, CYP2B6*6, ABCB1 (MDR1) c.3435>T, CCR5-del-32bp | 2 | √ | √ | |
MG2 Set F | IL28B (C/T Polymorphismus), IL6 (G174C), CYP3A4*22 | 2 | √ | √ |
DNA SEQUENCING | |||||
---|---|---|---|---|---|
Survey name | Description | Number of surveys | Surveys 2024 | ||
SQ 1/24 | SQ 2/24 | ||||
Dispatch date | Mar | Aug | |||
SQ | DNA Sequencing (Sequencing and corresponding diagnostic interpretation) | 2 | √ | √ | |
DNA ISOLATION | |||||
Survey name | Description | Number of surveys | Surveys 2024 | ||
DI 1/24 | DI 2/24 | ||||
Dispatch date | Mar | Aug | |||
DI | DNA Isolation (DNA Isolation and FV genotyping) The FV genotyping includes: FV-Leiden (ARG506GLN), FV-H1299R (HIS 1299ARG), FV-Cambridge (ARG306THR), FV-Hong-Kong (ARG306GLY), FII g20210a, MTHFR C677T, HFE (H63D, C282Y, S65C) | 2 | √ | √ |
NASCOLA Membership Dues and program charges are paid once, regardless of the number of PT/EQA Modules ordered. A NASCOLA membership account must be created before placing an order.
NASCOLA Membership Dues | |
Institutional Member (clinical labs)*……………………………… …$175 USDAssociate Member (vendors)*………………………………………..$1450 USDIndividual Member………………………………………………………….$50 USD*eligible to order PT/EQA modules |
Based on membership type, as outlined |
Program Fee Internet result submission and internet access to reports
|
175
|